Clinical Trial Update: Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) [Phase 2]

View source ↗

Summary

Phase II trial evaluating GM1 ganglioside to reduce or prevent paclitaxel-induced peripheral neuropathy in metastatic breast cancer has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Peripheral Neuropathy

Drugs mentioned

• GM1 ganglioside (GM1 ganglioside)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy | Phase 2 | Status: SUSPENDED